**b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Peptide Array, Influenza Virus A/California/04/2009 (H1N1)pdm09 Matrix Protein 1

# Catalog No. NR-18977

This reagent is the tangible property of the U.S. Government.

# For research use only. Not for human use.

# Contributor:

**BEI Resources** 

### Manufacturer:

New England Peptide, LLC.

### **Product Description:**

The 61-peptide array spans the matrix protein 1 (M1) of the A/California/04/2009 (H1N1)pdm09 strain of influenza virus (GenPept: ACP44152.1).<sup>1</sup> Peptides are 11- to 16-mers, with 10 to 12 amino acid overlaps. Please see Table 1 for length and sequence of individual peptides.

### Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

## Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with dessicants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

# Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2).

### Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water. Peptides that are not soluble in water can almost always be dissolved in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cellbased assays, 0.5% DMSO in medium is usually welltolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help

dissolution (see Table 2). These solvents may not be appropriate for certain applications, including cell-based assays.

# Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5-6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Array, Influenza Virus A/California/04/2009 (H1N1)pdm09 Matrix Protein 1, NR-18977."

### **Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see <u>www.cdc.gov/biosafety/publications/bmbl5/index.htm</u>.

#### **Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC<sup>®</sup> nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC<sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal.  $ATCC^{\circledast}$  and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government,  $ATCC^{\circledast}$ , their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 bei resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

### Use Restrictions:

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

### **References:**

 Garten, R. J., et al. "Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans." <u>Science</u> 325 (2009): 197-201. PubMed: 19465683. GenPept: ACP44152.1.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.



	1	Table 1
Peptide	Length	Sequence
01 of 61	15	1-MSLLTEVETYVLSII-15
02 of 61	16	5-TEVETYVLSIIPSGPL-20
03 of 61	15	9-TYVLSIIPSGPLKAE-23
04 of 61	15	13-SIIPSGPLKAEIAQR-27
05 of 61	15	17-SGPLKAEIAQRLESV-31
06 of 61	15	21-KAEIAQRLESVFAGK-35
07 of 61	15	25-AQRLESVFAGKNTDL-39
08 of 61	15	29-ESVFAGKNTDLEALM-43
09 of 61	15	33-AGKNTDLEALMEWLK-47
10 of 61	15	37-TDLEALMEWLKTRPI-51
11 of 61	15	41-ALMEWLKTRPILSPL-55
12 of 61	15	45-WLKTRPILSPLTKGI-59
13 of 61	15	49-RPILSPLTKGILGFV-63
14 of 61	15	53-SPLTKGILGFVFTLT-67
15 of 61	15	57-KGILGFVFTLTVPSE-71
16 of 61	15	61-GFVFTLTVPSERGLQ-75
17 of 61	15	65-TLTVPSERGLQRRRF-79
18 of 61	15	69-PSERGLQRRRFVQNA-83
19 of 61	15	73-GLQRRRFVQNALNGN-87
20 of 61	15	77-RRFVQNALNGNGDPN-91
21 of 61	14	82-NALNGNGDPNNMDR-95
22 of 61	15	85-NGNGDPNNMDRAVKL-99
23 of 61	15	89-DPNNMDRAVKLYKKL-103
24 of 61	15	93-MDRAVKLYKKLKREI-107
25 of 61	15	97-VKLYKKLKREITFHG-111
26 of 61	15	101-KKLKREITFHGAKEV-115
27 of 61	15	105-REITFHGAKEVSLSY-119
28 of 61	15	109-FHGAKEVSLSYSTGA-123
29 of 61	15	113-KEVSLSYSTGALASC-127
30 of 61	15	117-LSYSTGALASCMGLI-131
31 of 61	15	121-TGALASCMGLIYNRM-135
32 of 61	15	125-ASCMGLIYNRMGTVT-139
33 of 61	15	129-GLIYNRMGTVTTEAA-143
34 of 61	15	133-NRMGTVTTEAAFGLV-147
35 of 61	15	137-TVTTEAAFGLVCATC-151

bei resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

	Table 1				
Peptide	Length	Sequence			
36 of 61	15	141-EAAFGLVCATCEQIA-155			
37 of 61	15	145-GLVCATCEQIADSQH-159			
38 of 61	15	149-ATCEQIADSQHRSHR-163			
39 of 61	14	154-IADSQHRSHRQMAT-167			
40 of 61	16	157-SQHRSHRQMATTTNPL-172			
41 of 61	15	161-SHRQMATTTNPLIRH-175			
42 of 61	15	165-MATTTNPLIRHENRM-179			
43 of 61	15	169-TNPLIRHENRMVLAS-183			
44 of 61	15	173-IRHENRMVLASTTAK-187			
45 of 61	15	177-NRMVLASTTAKAMEQ-191			
46 of 61	15	181-LASTTAKAMEQMAGS-195			
47 of 61	15	185-TAKAMEQMAGSSEQA-199			
48 of 61	15	189-MEQMAGSSEQAAEAM-203			
49 of 61	15	193-AGSSEQAAEAMEVAN-207			
50 of 61	15	197-EQAAEAMEVANQTRQ-211			
51 of 61	15	201-EAMEVANQTRQMVHA-215			
52 of 61	15	205-VANQTRQMVHAMRTI-219			
53 of 61	16	209-TRQMVHAMRTIGTHPS-224			
54 of 61	15	213-VHAMRTIGTHPSSSA-227			
55 of 61	15	217-RTIGTHPSSSAGLKD-231			
56 of 61	15	221-THPSSSAGLKDDLLE-235			
57 of 61	15	225-SSAGLKDDLLENLQA-239			
58 of 61	15	229-LKDDLLENLQAYQKR-243			
59 of 61	15	233-LLENLQAYQKRMGVQ-247			
60 of 61	15	237-LQAYQKRMGVQMQRF-251			
61 of 61	11	242-KRMGVQMQRFK-252			

	Table 2				
Peptide	Solubility	Solvent			
01 of 61	1 mg/mL	100% DMSO			
02 of 61	1 mg/mL	50% acetonitrile in water			
03 of 61	1 mg/mL	50% acetonitrile in water			
04 of 61	1 mg/mL	50% acetonitrile in water			
05 of 61	1 mg/mL	50% acetonitrile in water			
06 of 61	1 mg/mL	50% acetonitrile in water			
07 of 61	1 mg/mL	50% acetonitrile in water			
08 of 61	1 mg/mL	50% acetonitrile in water			
09 of 61	1 mg/mL	50% acetonitrile in water			
10 of 61	1 mg/mL	50% acetonitrile in water			
11 of 61	1 mg/mL	50% acetonitrile in water			
12 of 61	1 mg/mL	50% acetonitrile in water			
13 of 61	1 mg/mL	50% acetonitrile in water			
14 of 61	1 mg/mL	50% acetonitrile in water			
15 of 61	1 mg/mL	100% acetic acid then 50% acetonitrile in water			

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

	Table 2				
Peptide	Solubility	Solvent			
16 of 61	1 mg/mL	50% acetonitrile in water			
17 of 61	1 mg/mL	50% acetonitrile in water			
18 of 61	1 mg/mL	50% acetonitrile in water			
19 of 61	1 mg/mL	50% acetonitrile in water			
20 of 61	1 mg/mL	50% acetonitrile in water			
21 of 61	1 mg/mL	50% acetonitrile in water			
22 of 61	1 mg/mL	50% acetonitrile in water			
23 of 61	1 mg/mL	50% acetonitrile in water			
24 of 61	1 mg/mL	50% acetonitrile in water			
25 of 61	1 mg/mL	50% acetonitrile in water			
26 of 61	1 mg/mL	50% acetonitrile in water			
27 of 61	1 mg/mL	50% acetonitrile in water			
28 of 61	1 mg/mL	50% acetonitrile in water			
29 of 61	1 mg/mL	50% acetonitrile in water			
30 of 61	1 mg/mL	100% DMSO			
31 of 61	1 mg/mL	50% acetonitrile in water			
32 of 61	1 mg/mL	50% acetonitrile in water			
33 of 61	1 mg/mL	100% acetic acid then 50% acetonitrile in water			
34 of 61	1 mg/mL	50% acetonitrile in water			
35 of 61	1 mg/mL	100% DMSO			
36 of 61	1 mg/mL	5% TFA in water then dilute with 50% acetonitrile in water			
37 of 61	1 mg/mL	100% acetic acid then 50% acetonitrile in water			
38 of 61	1 mg/mL	50% acetonitrile in water			
39 of 61	1 mg/mL	50% acetonitrile in water			
40 of 61	1 mg/mL	50% acetonitrile in water			
41 of 61	1 mg/mL	50% acetonitrile in water			
42 of 61	1 mg/mL	50% acetonitrile in water			
43 of 61	1 mg/mL	50% acetonitrile in water			
44 of 61	1 mg/mL	50% acetonitrile in water			
45 of 61	1 mg/mL	50% acetonitrile in water			
46 of 61	1 mg/mL	50% acetonitrile in water			
47 of 61	1 mg/mL	50% acetonitrile in water			
48 of 61	1 mg/mL	50% acetonitrile in water, then base			
49 of 61	1 mg/mL	100% acetic acid then 50% acetonitrile in water			
50 of 61	1 mg/mL	50% acetonitrile in water			
51 of 61	1 mg/mL	50% acetonitrile in water			
52 of 61	1 mg/mL	50% acetonitrile in water			
53 of 61	1 mg/mL	50% acetonitrile in water			
54 of 61	1 mg/mL	50% acetonitrile in water			
55 of 61	1 mg/mL	50% acetonitrile in water			
56 of 61	1 mg/mL	50% acetonitrile in water			
57 of 61	1 mg/mL	50% acetonitrile in water			
58 of 61	1 mg/mL	50% acetonitrile in water			
59 of 61	1 mg/mL	50% acetonitrile in water			
60 of 61	1 mg/mL	50% acetonitrile in water			
61 of 61	1 mg/mL	50% acetonitrile in water			

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898